SCHEMBL2220464

SCHEMBL2220464

O=C(C=Cc1ccc(I)cc1)c1ccc(OCCCCCCO)cc1

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 2/20 0.60
▸ BCHE P06276 11/20 0.57
▸ ACHE P22303 10/20 0.57
▸ HRH3 Q9Y5N1 1/20 0.55
▸ MAOB P27338 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12517328 1.00 ABCG2 (0.60) ABCG2BCHEACHEHRH3MAOB
SCHEMBL2220468 1.00 ABCG2 (0.60) ABCG2BCHEACHEHRH3MAOB
SCHEMBL25191766 0.93 ABCG2 (0.67) ABCG2BCHEACHEHRH3MAOB
SCHEMBL25204473 0.91 ABCG2 (0.60) ABCG2BCHEACHEHRH3MAOB
SCHEMBL25204475 0.91 ABCG2 (0.60) ABCG2BCHEACHEHRH3MAOB
SCHEMBL20608176 0.88 ABCG2 (0.70) ABCG2BCHEACHEHRH3MAOB
SCHEMBL18481042 0.88 ABCG2 (0.70) ABCG2BCHEACHEHRH3MAOB
SCHEMBL25209362 0.87 ABCG2 (0.60) ABCG2BCHEACHEHRH3MAOB
SCHEMBL7058879 0.87 MAOB (0.70) ABCG2BCHEACHEMAOB
SCHEMBL2993330 0.87 MAOB (0.68) ABCG2BCHEACHEHRH3MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 — — US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 — — US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 — — WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 — — EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 — — US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 — — WO disclosed
US-8362151-B2 Hybrid polymer materials for liquid crystal alignment layers ELSICON, INC. (US) 2013-01-29 — — US disclosed
EP-2513157-A1 HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS Li, Chunhong (US) 2012-10-24 — — EP disclosed
WO-2011084546-A1 HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS LI CHUNHONG (US) 2011-07-14 — — WO disclosed
US-20100305230-A1 HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS ELSICON, INC. (US) 2010-12-02 — — US disclosed
US-7632875-B2 Hybrid polymer materials for liquid crystal alignment layers ELSICON, INC. (US) 2009-12-15 — — US disclosed
US-20060051524-A1 Hybrid polymer materials for liquid crystal alignment layers ELSICON, INC. 2006-03-09 — — US disclosed
EP-1551898-A4 HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS ELSICON INC (US) 2006-01-11 — — EP disclosed
US-6919404-B2 Hybrid polymer materials for liquid crystal alignment layers ELSICON, INC. (US) 2005-07-19 — — US disclosed
EP-1551898-A1 HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS Elsicon, Inc. (US) 2005-07-13 — — EP disclosed
US-6900271-B2 Hybrid polymer materials for liquid crystal alignment layers ELSICON, INC (US) 2005-05-31 — — US disclosed
US-20030232927-A1 Hybrid polymer materials for liquid crystal alignment layers ELSICON, INC. 2003-12-18 — — US disclosed
US-20030232930-A1 Hybrid polymer materials for liquid crystal alignment layers ELSICON, INC. 2003-12-18 — — US disclosed
WO-2003102046-A1 HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS ELSICON, INC. (US) 2003-12-11 — — WO disclosed
WO-2003102045-A1 HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS ELSICON, INC. (US) 2003-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B ABCG2 1606/4885BCHE 588/4885ACHE 806/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 ABCG2 3622/4885BCHE 465/4885ACHE 656/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 ABCG2 3622/4885BCHE 465/4885ACHE 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback